GlassScriptPhysician profile
Manuel J Calvin
NPI 1396744678
$19,381.32
in general payments reported to CMS, 2019-2025
40 companies · $2,430 in 2025
The $2,430 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,851 · 2020: $1,593 · 2021: $2,798 · 2022: $3,773 · 2023: $3,444 · 2024: $3,494 · 2025: $2,430.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,095 · Education: $272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,095.45 |
| Education | $272.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,017.17 | 2019-2025 | Rinvoq, Skyrizi, Qulipta |
| Amgen INC. | $3,360.42 | 2019-2025 | Enbrel, Otezla, Tavneos |
| Ucb, INC. | $1,409.82 | 2019-2025 | Cimzia, Bimzelx |
| Janssen Biotech, INC. | $1,231.56 | 2019-2024 | Tremfya, Simponi Aria, Simponi |
| Novartis Pharmaceuticals Corporation | $1,093.91 | 2019-2025 | |
| Pfizer INC. | $1,068.23 | 2019-2025 | |
| Glaxosmithkline, LLC. | $878.05 | 2019-2025 | Benlysta |
| Lilly USA, LLC | $820.47 | 2019-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $644.94 | 2021-2025 | Saphnelo |
| Genentech USA, INC. | $515.76 | 2019-2025 | Actemra, Gazyva |
| Mallinckrodt Hospital Products INC. | $486.50 | 2020-2025 | Acthar |
| Horizon Therapeutics Plc | $423.28 | 2019-2023 | Krystexxa |
| E.R. Squibb & Sons, L.L.C. | $420.80 | 2019-2025 | Orencia |
| Aurinia Pharma U.S., INC. | $262.78 | 2021-2024 | Lupkynis |
| Boehringer Ingelheim Pharmaceuticals, INC. | $230.25 | 2019-2023 | Ofev |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Calvin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.